Secondary Lymphedema
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Herantis PharmaFinland - Espoo
2 programs1
1
Lymfactin®Phase 21 trial
Lymfactin® [1 x 10E10 vp]Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Herantis PharmaLymfactin®
Herantis PharmaLymfactin® [1 x 10E10 vp]
Novo NordiskIndocyanine Green
Clinical Trials (3)
Total enrollment: 82 patients across 3 trials
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
Start: Jun 2018Est. completion: Oct 202439 patients
Phase 2Completed
A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Start: Jun 2016Est. completion: Apr 202215 patients
Phase 1Terminated
Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment
Start: Sep 2018Est. completion: Aug 201928 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.